Clinical Trials Logo

Clinical Trial Summary

The investigators previously reported that angioplasty postconditioning reduces infarct size (cardiac enzyme release) in STEMI patients with a fully occluded coronary artery at hospital admission. Animal studies have suggested that the time window for applying brief episodes of ischemia and reperfusion aimed at triggering postconditioning's protection is very narrow, i.e. does not expand beyond 1 minute after reflow. We sought to address whether this window might be larger in humans, i.e. whether STEMI patients might be protected several minutes after undergoing spontaneous reperfusion before admission coronary angiography.

Therefore, STEMI patients (onset of chest pain less than 12 hours) with a TIMI flow grade > 1 were eligible for that study. Angioplasty postconditioning was completed as already published and infarct size was assessed by measuring cardiac enzymes release.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01483755
Study type Interventional
Source Hospices Civils de Lyon
Contact
Status Completed
Phase Phase 2
Start date July 2009
Completion date June 2012

See also
  Status Clinical Trial Phase
Recruiting NCT00989508 - Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Phase 2/Phase 3
Not yet recruiting NCT04570514 - Optimized Cardioprotection Therapy in Obese Subjects With AMI
Active, not recruiting NCT01857414 - Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI N/A
Completed NCT02342522 - Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI (CONDI2/ERIC-PPCI) N/A
Active, not recruiting NCT05462730 - Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction Phase 2
Completed NCT04397939 - Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19
Withdrawn NCT02098629 - Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction Phase 1/Phase 2
Completed NCT00586820 - Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI Phase 2
Completed NCT02390674 - Ciclosporin to Reduce Reperfusion Injury in Primary PCI Phase 2
Completed NCT00865722 - Remote Postconditioning in Patients With Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (PCI) Phase 2/Phase 3
Recruiting NCT01307371 - Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI) Phase 1
Completed NCT01379261 - Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction Phase 2/Phase 3
Completed NCT00881686 - Myocardial Protection With Adenosine Preconditioning Phase 1/Phase 2
Completed NCT00484575 - Inhaled Sevoflurane Compared to Intravenous Sedation Post Coronary Artery Bypass Grafting Phase 1/Phase 2
Recruiting NCT03995732 - Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury Phase 2
Recruiting NCT05775380 - The Role of Pioglitazone in Vascular Transcriptional Remodeling Phase 4
Completed NCT06450912 - Wall Strain Index Ratio as a Biomarker for Mechanical Complication of Hemorrhagic Myocardial Infarction
Completed NCT05354648 - Effects of Hypoxic-hyperoxic Preconditioning in Cardio-surgical Patients N/A
Completed NCT01601795 - Sevoflurane and Isoflurane - During Cardiopulmonary Bypass With the MECC System (Minimized Extracorporeal Circuit) Phase 4
Completed NCT01354808 - ACCEL-LOADING-ACS Study Phase 4